Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden

References

• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.
   PubMed Web of Science ®Google Scholar
• Diabetes UK. Facts and stats. 2016. Available from: https://www.diabetes.org.uk/Documents/Position%20statements/DiabetesUK_Facts_Stats_Oct16.pdf. [Accessed 2018 April 12].
   Google Scholar
• Gudbjörnsdottir S, Eliasson B, Cederholm J, et al. Nationella diabetesregistret, Årsrapport, 2016 års resultat. 2016. https://wwwndrnu/pdfs/Arsrapport_NDR_2016pdf. [Accessed 2018 April 12].
   Google Scholar
• Norhammar A, Bodegard J, Nystrom T, et al. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013. Diabetologia. 2016;59:1692–1701.
   PubMed Web of Science ®Google Scholar
• Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44:S14–S21.
   PubMed Web of Science ®Google Scholar
• Läkemedelsverket. Läkemedelsbehandling för glukoskontroll vid typ 2-diabetes – behandlingsrekommendation. 2017. Available from: https://lakemedelsverket.se/diabetestyp2. [Accessed 2018 April 12].
   Google Scholar
• Bolin K, Gip C, Mork AC, et al. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005–a register-based approach. Diabet Med. 2009;26:928–934.
   PubMed Web of Science ®Google Scholar
• Ringborg A, Martinell M, Stalhammar J, et al. Resource use and costs of type 2 diabetes in Sweden – estimates from population-based register data. Int J Clin Pract. 2008;62:708–716.
   PubMed Web of Science ®Google Scholar
• Steen Carlsson K, Andersson E, Lundquist A, et al. Påverkbara kostnader för typ 2-diabetes år 2020 och år 2030 i Sverige. Prognoser med IHE Cohort Model of Type 2 Diabetes. 2015. Available from: https://ihe.se/publicering/paverkbara-kostnader-typ-2-diabetes-ar-2020-och-ar-2030-sverige-prognoser-med-ihe-cohort-model-type-2-diabetes/ [Accessed 2018 April 12].
   Google Scholar
• Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308:581–590.
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Lay AL, Kumar M, et al. The association between body mass index and health and economic outcomes in the United States. J Occup Environ Med. 2015;57:1047–1054.
   PubMed Web of Science ®Google Scholar
• Li Q, Blume SW, Huang JC, et al. The economic burden of obesity by glycemic stage in the United States. Pharmacoeconomics. 2015;33:735–748.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V, Ben-Joseph RH. The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States. Obesity. 2008;16:2155–2162.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation (IDF) Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012. Available from: https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes. [Accessed 2018 April 12].
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes - 2019. Diabetes Care. 2019;2:S1–S186.
   Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–2701.
   PubMed Web of Science ®Google Scholar
• National diabetes register. Available from: https://www.ndr.nu/#/knappen. [Accessed 2018 April 12].
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endo. 2017;5:251–260.
   PubMed Web of Science ®Google Scholar
• Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endo. 2017;5:341–354.
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Dia Care. 2018;41:258–266.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endo. 2017;5:355–366.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291–2301.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endo. 2018;6:275–286.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Lundqvist A, Steen Carlsson K, Johansen P, et al. Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS One. 2014;9:e110235.
   PubMed Web of Science ®Google Scholar
• Kiadaliri AA, Gerdtham UG, Eliasson B, et al. Cost-utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn basal insulin as add-on to metformin in type 2 diabetes in Sweden. Diabetes Ther. 2014;5:591–607.
   PubMed Web of Science ®Google Scholar
• Steen Carlsson K, Persson U. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. J Med Econ. 2014;17:658–669.
   PubMedGoogle Scholar
• Ericsson A, Lundqvist A. Cost effectiveness of insulin degludec plus liraglutide (IDegLira) in a fixed combination for uncontrolled type 2 diabetes mellitus in Sweden. Appl Health Econ Health Policy. 2017;15:237–248.
   PubMed Web of Science ®Google Scholar
• SCB. Consumer price index for health. Available from: http://www.scb.se/en_/Finding-statistics/Statistics-by-subject-area/Prices-and-Consumption/Consumer-Price-Index/Consumer-Price-Index-CPI/Aktuell-Pong/33779/Consumer-Price-Index-CPI/33907/. [Accessed 2018 April 12].
   Google Scholar
• TLV. 2015. Available from: https://www.tlv.se/download/18.467926b615d084471ac3367e/1510316392137/bes150522-trulicity.pdf. [Accessed 2018 April 12].
   Google Scholar
• European Medicines Agency. Dulaglutide (Trulicity®) summary of product characteristics. 2014. Available from: https://www.ema.europa.eu/documents/product-information/trulicity-epar-product-information_en.pdf. [Accessed 2018 April 12].
   Google Scholar
• Witkowski M, Wilkinson L, Webb N, et al. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin. Diabetes Ther. 2018;9:1233–1251.
   PubMed Web of Science ®Google Scholar
• Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136–145.
   PubMed Web of Science ®Google Scholar
• Ward AJ, Salas M, Caro JJ, et al. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the U.K. Cost Eff Resour Alloc. 2004;2:1–9.
   Google Scholar
• Willis M, Asseburg C, Nilsson A, et al. Multivariate prediction equations for HbA1c lowering, weight change, and hypoglycemic events associated with insulin rescue medication in type 2 diabetes mellitus: informing economic modeling. Value Health. 2017;20:357–371.
   PubMed Web of Science ®Google Scholar
• Chaudhry ZW, Gannon MC, Nuttall FQ. Stability of body weight in type 2 diabetes. Diabetes Care. 2006;29:493–497.
   PubMed Web of Science ®Google Scholar
• Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health. 2006;9:193–198.
   PubMed Web of Science ®Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665–671.
   PubMed Web of Science ®Google Scholar
• Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, et al. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ. 2013;16:1453–1461.
   PubMedGoogle Scholar
• Statistics Sweden. Salary structures, whole economy, Average monthly salary 2014–2016. Available from: http://www.statistikdatabasen.scb.se/pxweb/sv/ssd/START__AM__AM0110__AM0110C/LonSNIKon/table/tableViewLayout1/?rxid=11a7e405-b69f-406a-8271-a0159f766f9d. [Accessed 2018 April 12].
   Google Scholar
• Sorensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Res Int. 2013; Article ID 618039. Available from: http://dx.doi.org/10.1155/2013/618039
   Google Scholar
• Yu S, Schwab P, Bian B, et al. Use of add-on treatment to metformin monotherapy for patients with Type 2 diabetes and suboptimal glycemic control: a U.S. Database Study. JMCP. 2016;22:272–280.
   PubMedGoogle Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417.
   PubMed Web of Science ®Google Scholar
• Home PD, Boulton AJM, Jimenez J, et al. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diab Int. 2003;20:63–71.
   Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682–689.
   PubMed Web of Science ®Google Scholar
• Dushay J, Abrahamson MJ. Insulin therapy for type 2 diabetes: making it work. J Fam Pract. 2010;59:E1–8.
   PubMed Web of Science ®Google Scholar
• Johansen P, Hakan-Bloch J, Liu AR, et al. Cost-effectiveness of once-weekly semaglutide 1.0 mg vs. dulaglutide 1.5 mg as add-on to metformin in the treatment of type 2 diabetes in Canada. Diabetes. 2018;67.
   Web of Science ®Google Scholar
• Viljoen A, Hoxer CS, Johansen P, et al. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes Obes Metab. 2019;21:611–621.
   PubMed Web of Science ®Google Scholar
• Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237–240.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Niessner A, Tamargo J, Koller L, et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J. 2018;39:2274–2281.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20:S5–S26.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar